Cargando…
Leukopenia and agranulocytosis in atypical antipsychotic treatment - besides clozapine
INTRODUCTION: Leukopenia and agranulocytosis are reported and dangerous haematological side-effects associated with the use of antipsychotics, mostly reported for clozapine administration. However, increased case reports about severe abnormalities even during treatment with second generation antipsy...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9470434/ http://dx.doi.org/10.1192/j.eurpsy.2021.2112 |
_version_ | 1784788843172462592 |
---|---|
author | Jorge, B. Fernandes, C. Pedro Carvalho, J. |
author_facet | Jorge, B. Fernandes, C. Pedro Carvalho, J. |
author_sort | Jorge, B. |
collection | PubMed |
description | INTRODUCTION: Leukopenia and agranulocytosis are reported and dangerous haematological side-effects associated with the use of antipsychotics, mostly reported for clozapine administration. However, increased case reports about severe abnormalities even during treatment with second generation antipsychotics other than clozapine. OBJECTIVES: This review aims to compare haematological abnormalities associated with clozapine vs non-clozapine antipsychotic treatment, regarding aspects such as safety levels or the need for regular blood samples monitoring. METHODS: Pubmed and Google Scholar were searched for eligible articles, through keyword search and cross-referencing. RESULTS: Neutropenia is common both in patients with schizophrenia on clozapine treatment and in those never on clozapine. Cases of agranulocytosis has been described with the use of olanzapine, risperidone or paliperidone, that do not have the same monitoring regulatory process as clozapine. CONCLUSIONS: These results highlight the challenges in identifying and managing non-clozapine antipsychotic-induced leukopenia in susceptible patients. Continued research in this domain for evidence based management of antipsychotic-induced blood dyscrasias DISCLOSURE: No significant relationships. |
format | Online Article Text |
id | pubmed-9470434 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Cambridge University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-94704342022-09-29 Leukopenia and agranulocytosis in atypical antipsychotic treatment - besides clozapine Jorge, B. Fernandes, C. Pedro Carvalho, J. Eur Psychiatry Abstract INTRODUCTION: Leukopenia and agranulocytosis are reported and dangerous haematological side-effects associated with the use of antipsychotics, mostly reported for clozapine administration. However, increased case reports about severe abnormalities even during treatment with second generation antipsychotics other than clozapine. OBJECTIVES: This review aims to compare haematological abnormalities associated with clozapine vs non-clozapine antipsychotic treatment, regarding aspects such as safety levels or the need for regular blood samples monitoring. METHODS: Pubmed and Google Scholar were searched for eligible articles, through keyword search and cross-referencing. RESULTS: Neutropenia is common both in patients with schizophrenia on clozapine treatment and in those never on clozapine. Cases of agranulocytosis has been described with the use of olanzapine, risperidone or paliperidone, that do not have the same monitoring regulatory process as clozapine. CONCLUSIONS: These results highlight the challenges in identifying and managing non-clozapine antipsychotic-induced leukopenia in susceptible patients. Continued research in this domain for evidence based management of antipsychotic-induced blood dyscrasias DISCLOSURE: No significant relationships. Cambridge University Press 2021-08-13 /pmc/articles/PMC9470434/ http://dx.doi.org/10.1192/j.eurpsy.2021.2112 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Abstract Jorge, B. Fernandes, C. Pedro Carvalho, J. Leukopenia and agranulocytosis in atypical antipsychotic treatment - besides clozapine |
title | Leukopenia and agranulocytosis in atypical antipsychotic treatment - besides clozapine |
title_full | Leukopenia and agranulocytosis in atypical antipsychotic treatment - besides clozapine |
title_fullStr | Leukopenia and agranulocytosis in atypical antipsychotic treatment - besides clozapine |
title_full_unstemmed | Leukopenia and agranulocytosis in atypical antipsychotic treatment - besides clozapine |
title_short | Leukopenia and agranulocytosis in atypical antipsychotic treatment - besides clozapine |
title_sort | leukopenia and agranulocytosis in atypical antipsychotic treatment - besides clozapine |
topic | Abstract |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9470434/ http://dx.doi.org/10.1192/j.eurpsy.2021.2112 |
work_keys_str_mv | AT jorgeb leukopeniaandagranulocytosisinatypicalantipsychotictreatmentbesidesclozapine AT fernandescpedro leukopeniaandagranulocytosisinatypicalantipsychotictreatmentbesidesclozapine AT carvalhoj leukopeniaandagranulocytosisinatypicalantipsychotictreatmentbesidesclozapine |